Abstract
We aimed to compare the effects of two different vasodilating principles, angiotensin II-receptor blockade and calcium channel blockade, on peripheral insulin-mediated glucose uptake in patients with hypertension and other cardiovascular risk factors. Twenty-one hypertensive patients (11 women and 10 men) with mean age 58.6 years (range 46–75 years), body mass index 29.2±1.0 kg/m2 and blood pressure 160±3/96±2 mm Hg entered a 4-week run-in period with open-label amlodipine 5 mg. Thereafter they were randomized double-blindly to additional treatment with amlodipine 5 mg or losartan 100 mg. After 8 weeks of treatment, all patients underwent clinical examination and laboratory testing, and 17 of them underwent a hyperinsulinaemic isoglycaemic glucose clamp. After a 4-week open-label wash-out phase, the participants crossed over to the opposite treatment regimen and final examinations with hyperinsulinaemic isoglycaemic glucose clamp after another 8 weeks. Blood pressure was lowered to the same level in both treatment periods. The glucose disposal rate was significantly higher after treatment with losartan 100 mg+amlodipine 5 mg compared to amlodipine 10 mg (4.9±0.4 vs 4.2±0.5 mg/kg/min, P=0.039). Thus our data suggest that angiotensin II-receptor blockade with losartan improves glucose metabolism at the cellular level beyond what can be expected by the vasodilatation and blood pressure reduction alone.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kannel WB, Wilson PW, Zhang TJ . The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991; 121 (Part 2): 1268–1273.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J . Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365 (9455): 217–223.
Zimmet P, Alberti KG, Shaw J . Global and societal implications of the diabetes epidemic. Nature 2001; 414 (6865): 782–787.
Padwal R, Laupacis A . Antihypertensive therapy and incidence of type II diabetes: a systematic review. Diabetes Care 2004; 27 (1): 247–255.
Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL . Hypertension and antihypertensive therapy as risk factors for type II diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000; 342 (13): 905–912.
Aksnes TA, Reims HM, Kjeldsen SE, Mancia G . Antihypertensive treatment and new-onset diabetes mellitus. Curr Hypertens Rep 2005; 7 (4): 298–303.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022–2031.
DeFronzo RA, Tobin JD, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237 (3): E214–E223.
Moan A, Nordby G, Os I, Birkeland KI, Kjeldsen SE . Relationship between hemorrheologic factors and insulin sensitivity in healthy young men. Metabolism 1994; 43 (4): 423–427.
Fossum E, Höieggen A, Moan A, Nordby G, Kjeldsen SE . Insulin sensitivity relates to other cardiovascular risk factors in young men: validation of some modifications of the hyperinsulinaemic, isoglycaemic glucose clamp technique. Blood Press Suppl 1997; 2: 113–119.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412–419.
Moan A, Höieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE . The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14 (9): 1093–1097.
Howard BV, Rodriguez BL, Bennett PH, Harris MI, Hamman R, Kuller LH et al. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 2002; 105 (18): e132–e137.
Pacini G, Mari A . Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003; 17 (3): 305–322.
Bergman RN, Finegood DT, Ader M . Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6 (1): 45–86.
Lender D, rauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P . A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12 (3): 298–303.
Opie LH, Schall R . Old antihypertensives and new diabetes. J Hypertens 2004; 22 (8): 1453–1458.
Schiffrin EL, Park JB, Intengan HD, Touyz RM . Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101 (14): 1653–1659.
Julius S, Gudbrandsson T, Jamerson K, Tariq SS, Andersson O . The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9 (11): 983–986.
Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43 (5): 993–1002.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U . Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109 (17): 2054–2057.
Carlsson PO, Berne C, Jansson L . Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41 (2): 127–133.
Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC . Angiotensin blockade prevents type II diabetes by formation of fat cells. Hypertension 2002; 40 (5): 609–611.
Moan A, Risanger T, Eide I, Kjeldsen SE . The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3 (3): 185–188.
Olsen MH, Fossum E, Höieggen A, Wachtell K, Hjerkinn E, Nesbitt SD et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23 (4): 891–898.
Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B et al. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002; 20 (9): 1879–1886.
Acknowledgements
We thank biochemist Roseli Andreassen for technical assistance and the Department of Clinical Chemistry at Ullevaal University Hospital and Dr Knut Lande for analyzing glucose, HbA1c, lipids and uric acid. We also thank Merck & Co., USA for school grant support. We are indebted to physicians and staff at Bentsebro legesenter, Collosseumklinikken, Ekeberg legesenter, L11 Familiehelsesenter, Manglerud legekontor, Nordseter legekontor, Nordstrand legekontor and Trosterud legekontor in Oslo for their kind help with recruiting patients.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aksnes, T., Reims, H., Guptha, S. et al. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 20, 860–866 (2006). https://doi.org/10.1038/sj.jhh.1002087
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002087
Keywords
This article is cited by
-
An association between angiotensin II type 2 receptor gene A/C3123 polymorphism and glycemic control marker in a general Japanese population
Molecular Biology Reports (2009)
-
New onset diabetes: can it be delayed?
Journal of Human Hypertension (2008)
-
Measurements of insulin resistance in hypertension: where are we now?
Journal of Human Hypertension (2007)